Purpose To study the effect of interferon-α2 auto-antibodies (IFN-α2 Abs) on clinical and
virological outcomes in critically ill COVID-19 patients and the risk of IFN-α2 Abs transfer …

Purpose Six to 19% of critically ill COVID-19 patients display circulating auto-antibodies
against type I interferons (IFN-AABs). Here, we establish a clinically applicable strategy for …

Background In a recent study, autoantibodies neutralizing type I interferons (IFNs) were
present in at least 10% of cases of critical COVID-19 pneumonia. These autoantibodies …

Objectives Impairment of type I interferon (IFN‐I) immunity has been reported in critically ill
COVID‐19 patients. This defect can be explained in a subset of patients by the presence of …

Purpose To report four cases of life-threatening COVID-19 pneumonia in patients with high
blood concentrations of neutralizing autoantibodies against type I interferons (IFNs), who …

To the Editor, Bastard et al. reported that autoantibodies neutralizing type I interferons (IFN)
s are found in at least 18% of deceased COVID-19 patients [1]. They also showed that the …

Background It is important to predict which patients infected by SARS-CoV-2 are at higher
risk of life-threatening COVID-19. Several studies suggest that neutralizing auto-antibodies …

Introduction Impairment of the type I interferon (IFN–I) signaling pathway is associated with
increased severity of COVID-19 disease. Here we have undertaken a systematic review and …

Abstract Background Auto-antibodies (auto-Abs) neutralizing type I interferons (IFN) have
been found in about 15% of critical cases COVID-19 pneumonia and less than 1% of mild or …

Purpose Autoantibodies (aAbs) to type I interferons (IFNs) have been found in less than 1%
of individuals under the age of 60 in the general population, with the prevalence increasing …